Ann Gastroenterol. 2014;27(1):53-59.

Significance of the .

Annals of gastroenterology

Dimitrios Konstantinou, Ekaterini Margariti, Emilia Hadziyannis, Dimitrios Pectasides, George V Papatheodoridis

PMID: 24714782 PMCID: PMC3959537

Abstract

BACKGROUND: The 13C-caffeine breath test (CBT) is a non-invasive, quantitative test of liver function which has been shown to correlate inversely to the Child-Pugh score. The aim of the study was to determine the utility of CBT in the assessment of cirrhosis and its correlation to the model for end-stage liver disease (MELD) score.

METHODS: Thirty-nine patients, 29 with cirrhosis and 10 with chronic liver disease without cirrhosis, and 8 healthy volunteers were included. Cirrhotic patients were graded according to Child-Pugh and MELD scores. All participants underwent CBT and laboratory tests on the same day. The results of the CBT were expressed as percentages of changes over baseline values (Δ‰) per 100 mg caffeine.

RESULTS: The mean single 15-min, 30-min, 45-min and 1-h CBT results, as well as cumulative CBT values differed significantly between healthy controls or chronic liver disease patients and cirrhotics (1-h CBT: 3.22±1.06 or 3.56±2.80 vs. 1.69±2.52, P≤0.01). In contrast, the CBT results at any time point or cumulative values did not correlate with MELD or Child-Pugh scores. Receiver operating characteristics (ROC) analysis showed that the 30-min CBT values were more accurate in differentiating cirrhotics from chronic liver disease patients (area under ROC curve: 0.871).

CONCLUSIONS: CBT can reliably differentiate the patients with decompensated cirrhosis from non-cirrhotic patients with chronic liver diseases. However, in patients with decompensated cirrhosis, CBT results do not seem to be associated with the Child-Pugh and MELD scores.

Keywords: Caffeine breath test; Child-Pugh; MELD; cirrhosis

References

1. Hepatology. 1984 Jan-Feb;4(1):38-46 - PubMed
2. BMC Gastroenterol. 2002;2:2 - PubMed
3. Pharmacogenetics. 2002 Aug;12(6):473-8 - PubMed
4. Nat Clin Pract Gastroenterol Hepatol. 2005 Jan;2(1):24-30 - PubMed
5. J Hepatol. 2005;42 Suppl(1):S100-7 - PubMed
6. Hepatology. 2003 Nov;38(5):1227-36 - PubMed
7. Best Pract Res Clin Gastroenterol. 2011 Apr;25(2):281-90 - PubMed
8. Hepatology. 1995 Jan;21(1):120-8 - PubMed
9. Clin Pharmacol Ther. 1982 Jul;32(1):98-106 - PubMed
10. Prog Clin Biol Res. 1983;135:119-45 - PubMed
11. Br J Surg. 1973 Aug;60(8):646-9 - PubMed
12. J Hepatol. 1992 Mar;14(2-3):157-62 - PubMed
13. Clin Pharmacol Ther. 1978 Jul;24(1):40-5 - PubMed
14. Lancet. 2008 Mar 8;371(9615):838-51 - PubMed
15. Xenobiotica. 1998 Dec;28(12):1129-65 - PubMed
16. Pharmacogenetics. 2004 Jan;14(1):1-18 - PubMed
17. Scand J Gastroenterol. 1999 Sep;34(9):942-3 - PubMed
18. Clin Pharmacol Ther. 1991 Nov;50(5 Pt 1):508-19 - PubMed
19. Eur J Clin Pharmacol. 1983;24(1):93-8 - PubMed
20. Clin Pharmacol Ther. 1984 Jul;36(1):133-7 - PubMed
21. Br J Clin Pharmacol. 1980 Jan;9(1):11-9 - PubMed
22. J Gastroenterol Hepatol. 2011 Sep;26(9):1411-6 - PubMed
23. J Gastroenterol Hepatol. 2003 Apr;18(4):445-9 - PubMed
24. Hepatology. 1988 May-Jun;8(3):575-9 - PubMed
25. Dis Markers. 2011;31(3):121-8 - PubMed
26. J Hepatol. 2004 Jun;40(6):897-903 - PubMed
27. Br J Clin Pharmacol. 1994 Dec;38(6):573-6 - PubMed
28. Hepatology. 2000 Apr;31(4):864-71 - PubMed
29. Dig Dis Sci. 2011 Apr;56(4):977-87 - PubMed
30. Adv Exp Med Biol. 1991;283:407-11 - PubMed
31. Clin Pharmacol Ther. 1979 Oct;26(4):483-92 - PubMed
32. Aliment Pharmacol Ther. 2005 Sep 1;22(5):395-403 - PubMed
33. J Clin Gastroenterol. 2008 Apr;42(4):408-12 - PubMed
34. Zhonghua Yi Xue Za Zhi (Taipei). 1996 May;57(5):329-34 - PubMed
35. Drugs. 2009;69(13):1739-60 - PubMed
36. Gastroenterology. 2003 Jan;124(1):91-6 - PubMed

Publication Types

• Journal Article